RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug aims to outsmart Treatment-Resistant myeloma
Disease control Not yet recruitingThis phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune syste…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis Phase 2 trial is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have already tried lenali…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC